- Home
- JANX vs RIGL Comparison
JANX vs RIGL Comparison
Compare JANX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | RIGL |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 911.8M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JANX | RIGL |
|---|---|---|
| Price | $16.71 | $48.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | $36.24 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 746.1K | 190.3K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | $10,000,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $194.24 | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $37.08 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $12.12 | $24.84 |
| 52 Week High | $35.34 | $52.24 |
Technical Indicators
Market Signals| Indicator | JANX | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 53.51 |
| Support Level | $15.83 | $44.50 |
| Resistance Level | $19.16 | $50.19 |
| Average True Range (ATR) | 0.91 | 1.76 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 16.32 | 55.99 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.